Materials are not handled and stored in a manner to prevent contamination and ensure proper identification.
Inspection Record
ChemPacific Corporation — FDA 483 Findings
Inspectors Yaharn SuThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The firm failed to maintain adequate quality control systems, including data integrity controls and procedural oversight, Specifically, a.
The firm failed to have an ongoing testing program designed to monitor the stability characteristics of active pharmaceutical ingredients.
Buildings used in the manufacture, processing, packing, or holding of intermediates and API are not maintained in a good state of repair and kept in a clean condition.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.